Grifols, S.A.

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME Other stock markets 11:35:09 2024-07-17 EDT			After market 13:31:45
9.2 ^EUR	+0.61%		9.348	+1.61%

05:11pm	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
07-16	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT

Grifols, S.A. acquired 49% stake in Access Biologicals, L.L.C. for $51 million.

January 11, 2017

Grifols, S.A. (BME:GRF) acquired 49% stake in Access Biologicals, L.L.C. for $51 million on January 12, 2017. Osborne Clarke and Proskauer Rose acted as legal advisors for Grifols, S.A. Grifols, S.A. (BME:GRF) completed the acquisition of 49% stake in Access Biologicals, L.L.C on January 12, 2017.

Latest news about Grifols, S.A.

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	11:11am	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	07-16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	07-15	MT
Moody's Removes Rating of Spanish Pharmaceutical Grifols	07-14	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	07-11	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	07-10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	07-09	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday	07-09	MT
Grifols Shares Surge on Take-Private Talks	07-09	MT
Europe's STOXX 600 dips ahead of Powell testimony; Indivior sinks	07-09	RE
ADRs Slump; SYLA Technologies Declines 35%	07-08	DJ
European Equities Close Mixed in Monday Trading	07-08	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	07-08	MT
GRIFOLS : A strategic move or a ploy to arrest further shareholder wealth erosion?	07-08
That's not so bad, is it?	07-08
Top Premarket Gainers	07-08	MT
Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid	07-08	CI
TSX futures muted as commodities decline amid rate cut hopes	07-08	RE
Trending : Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker	07-08	DJ
Grifols Receives Takeover Interest from Founding Family, Brookfield; Shares Suspended	07-08	MT
Grifols Faces Delisting Bid From Founding Family and Brookfield	07-08	DJ
Grifols Receives Takeover Interest from Founding Family, Brookfield; Shares Suspended	07-08	MT
Grifols says founding family, Brookfield looking to delist drugmaker	07-08	RE
Grifols Receives Takeover Interest from Founding Family, Brookfield	07-08	MT
Brookfield Capital Partners (Uk) Limited and Grifols family reached an agreement to acquire remaining stake Grifols, S.A..	07-07	CI

Chart Grifols, S.A.

Duration

Period

More charts

Company Profile

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , IBEX 35

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GRIFOLS : A strategic move or a ploy to arrest further shareholder wealth erosion?

July 08, 2024 at 08:50 am

Gotham City sets its sights on Grifols

January 09, 2024 at 10:09 am

More Strategies

Ratings for Grifols, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.144 EUR

Average target price

17.22 EUR

Spread / Average Target

+88.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GRIFOLS, S.A.	-40.47%	6.26B
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	42.34B
BIOGEN INC.	-11.78%	32.76B
UCB	+79.34%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-12.50%	16.31B
INCYTE CORPORATION	+3.09%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.23B
ALTEOGEN INC.	+178.17%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	+1.80%	8.97B

Biopharmaceuticals

Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Grifols, S.A. acquired 49% stake in Access Biologicals, L.L.C. for $51 million.

EPS Revisions